Technical Analysis for RGNX - REGENXBIO Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -3.79% | |
| MACD Bearish Centerline Cross | Bearish | -3.79% | |
| Calm After Storm | Range Contraction | -3.79% | |
| Inside Day | Range Contraction | -3.79% | |
| Wide Bands | Range Expansion | -3.79% | |
| Fell Below 20 DMA | Bearish | -3.09% | |
| Calm After Storm | Range Contraction | -3.09% | |
| Wide Bands | Range Expansion | -3.09% | |
| 50 DMA Resistance | Bearish | -8.72% | |
| Crossed Above 20 DMA | Bullish | -8.72% |
| Alert | Time |
|---|---|
| Gap Down Partially Closed | about 1 hour ago |
| Gap Down Closed | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Down 5% | about 1 hour ago |
| Down 3% | about 1 hour ago |
Get this analysis on your stocks daily!
- Earnings date: 11/06/2024
REGENXBIO Inc. Description
REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Emerging Technologies Molecular Biology Gene Therapy Genetics Medical Genetics Macular Degeneration Applied Genetics Cholesterol Wet Age Related Macular Degeneration Gene Delivery Lipoprotein Hypercholesterolemia Retinitis Adeno Associated Virus Retinitis Pigmentosa Mucopolysaccharidosis Homozygous Familial Hypercholesterolemia Iduronidase Rgx X Linked Retinitis Pigmentosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.8 |
| 52 Week Low | 8.535 |
| Average Volume | 693,179 |
| 200-Day Moving Average | 14.28 |
| 50-Day Moving Average | 10.37 |
| 20-Day Moving Average | 9.79 |
| 10-Day Moving Average | 10.52 |
| Average True Range | 0.94 |
| RSI (14) | 46.24 |
| ADX | 21.3 |
| +DI | 24.26 |
| -DI | 26.06 |
| Chandelier Exit (Long, 3 ATRs) | 9.41 |
| Chandelier Exit (Short, 3 ATRs) | 11.34 |
| Upper Bollinger Bands | 11.61 |
| Lower Bollinger Band | 7.98 |
| Percent B (%b) | 0.45 |
| BandWidth | 37.12 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0003 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.82 | ||||
| Resistance 3 (R3) | 10.74 | 10.27 | 10.62 | ||
| Resistance 2 (R2) | 10.27 | 9.97 | 10.31 | 10.55 | |
| Resistance 1 (R1) | 9.95 | 9.78 | 10.11 | 10.03 | 10.49 |
| Pivot Point | 9.48 | 9.48 | 9.56 | 9.52 | 9.48 |
| Support 1 (S1) | 9.16 | 9.18 | 9.32 | 9.24 | 8.77 |
| Support 2 (S2) | 8.69 | 8.99 | 8.73 | 8.71 | |
| Support 3 (S3) | 8.37 | 8.69 | 8.64 | ||
| Support 4 (S4) | 8.45 |
